The effect of fampiridine on optic nerve imaging in patients with Anterior Ischemic Optic neuropathy

Investigating the effect of Fampiridine on visual parameters and optic nerve imaging in patients with Anterior Ischemic Optic neuropathy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20151123025202N35

Enrollment

Registered

2024-02-07

Start date

2024-03-20

Completion date

Unknown

Last updated

2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anterior Ischemic Optic neuropathy. Ischemic optic neuropathy

Interventions

Intervention 1: Intervention group: In addition to standard treatment and control of underlying risk factors such as diabetes and blood pressure, they will be treated with 10 mg fampiridine tablets fo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with anterior ischemic optic neuropathy Consent to participate in the study At least 3 months have passed since the onset of symptoms

Exclusion criteria

Exclusion criteria: Pregnancy History of seizures Renal failure

Design outcomes

Primary

Measure	Time frame
Acuity Visual. Timepoint: Pre treatment and 12 weeks post treatment. Method of measurement: Using ETDRS chart.;Field of vision. Timepoint: Pre treatment and 12 weeks post treatment. Method of measurement: Using automatic perimetry device.	—

Secondary

Measure	Time frame
Change inthickness of nerve cells. Timepoint: Pre treatment and 12 weeks post treatment. Method of measurement: Using Peripapillary-OCT.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbbas Moradi

Hamedan University of Medical Sciences

a.moradi@umsha.ac.ir+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026